Research programme: bispecific NK cell engaging antibodies - Innate Pharma/Sanofi

Drug Profile

Research programme: bispecific NK cell engaging antibodies - Innate Pharma/Sanofi

Alternative Names: Bispecific NK cell engagers - Innate Pharma/Sanofi

Latest Information Update: 14 Jan 2016

Price : $50

At a glance

  • Originator Innate Pharma
  • Developer Innate Pharma; Sanofi
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action Immunostimulants; Natural cytotoxicity triggering receptor 1 agonists; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 10 Jan 2016 Early research in Cancer in France (Parenteral)
  • 10 Jan 2016 Innate Pharma and Sanofi agree to co-develop Bispecific NK cell engaging antibodies for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top